Harvard Bioscience Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Harvard Bioscience Inc. has filed its 2023 annual report on Form 10-K, detailing its financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

HARVARD BIOSCIENCE INC (HBIO) filed a Annual Report (10-K) with the SEC on March 7, 2024. Harvard Bioscience Inc. filed its annual report for the fiscal year ended December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal executive offices are located at 84 October Hill Rd, Holliston, MA 01746. James Green serves as Chairman, President, and Chief Executive Officer. The filing was submitted on March 7, 2024.

Why It Matters

For investors and stakeholders tracking HARVARD BIOSCIENCE INC, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Harvard Bioscience's financial health, operational activities, and strategic direction for the past fiscal year, which is crucial for investors to assess the company's performance and future prospects. The detailed financial statements and risk factors disclosed in this report are essential for stakeholders to understand the company's financial position, potential risks, and compliance with regulatory requirements.

Risk Assessment

Risk Level: low — HARVARD BIOSCIENCE INC shows low risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant negative or positive financial events, indicating a routine disclosure.

Analyst Insight

Review the detailed financial statements and management discussion within the 10-K to understand the company's performance drivers and any emerging trends.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed Period of Report)
• 2024-03-07 — Filing Date (Date Filed)
• 3826 — Standard Industrial Classification (Laboratory Analytical Instruments)
• DE — State of Incorporation (Incorporation State)

Key Players & Entities

• HARVARD BIOSCIENCE INC (company) — Filer
• James Green (person) — Chairman, President and Chief Executive Officer
• 84 OCTOBER HILL RD (company) — Business Address
• HOLLISTON (company) — City
• MA (company) — State
• 01746 (company) — ZIP Code
• 20231231 (date) — Fiscal Year End
• 20240307 (date) — Filing Date

FAQ

Industry Context

Harvard Bioscience Inc. operates in the laboratory analytical instruments industry, providing a range of products and services to scientific research and clinical diagnostic markets.

Regulatory Implications

The company is subject to standard SEC regulations for public companies, including the requirement to file annual reports (Form 10-K) detailing financial performance and business operations.

What Investors Should Do

1. Analyze the full 10-K document for detailed financial statements and management's discussion and analysis.
2. Identify any specific operational or financial risks disclosed in the risk factors section.
3. Review executive compensation details if available in the full filing.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K filing.
• 2024-03-07: Filing Date — Date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This is the initial filing of the 2023 Form 10-K, providing the latest annual financial and operational data for Harvard Bioscience Inc.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value HBIO The Nasdaq Global Ma
• $1,000 — ducts and services range typically from $1,000 to over $100,000. Our products include
• $100,000 — ces range typically from $1,000 to over $100,000. Our products include spectrophotometer
• $11.8 million — development expenses were approximately $11.8 million and $12.3 million for the years ended D
• $12.3 million — es were approximately $11.8 million and $12.3 million for the years ended December 31, 2023 a

Filing Documents

• hboi20231231_10k.htm (10-K) — 1729KB
• ex_632408.htm (EX-21.1) — 6KB
• ex_632409.htm (EX-23.1) — 3KB
• ex_632410.htm (EX-31.1) — 13KB
• ex_632411.htm (EX-31.2) — 12KB
• ex_632412.htm (EX-32.1) — 4KB
• ex_632413.htm (EX-32.2) — 4KB
• ex_632414.htm (EX-97) — 14KB
• 0001171843-24-001239.txt (&nbsp;) — 10000KB
• hbio-20231231.xsd (EX-101.SCH) — 91KB
• hbio-20231231_cal.xml (EX-101.CAL) — 75KB
• hbio-20231231_def.xml (EX-101.DEF) — 585KB
• hbio-20231231_lab.xml (EX-101.LAB) — 539KB
• hbio-20231231_pre.xml (EX-101.PRE) — 645KB
• hboi20231231_10k_htm.xml (XML) — 1793KB

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 7 Item 1B. Unresolved Staff Comments 15 Item 1C. Cybersecurity 15 Item 2.

Properties

Properties 15 Item 3.

Legal Proceedings

Legal Proceedings 16 Item 4. Mine Safety Disclosures 16 PART II 16 Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 16 Item 6. [Reserved] 16 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 21 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 21 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 21 Item 9A.

Controls and Procedures

Controls and Procedures 21 Item 9B. Other Information 24 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 24 PART III 24 Item 10. Directors, Executive Officers and Corporate Governance 24 Item 11.

Executive Compensation

Executive Compensation 24 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 24 Item 13. Certain Relationships and Related Transactions, and Director Independence 24 Item 14. Principal Accounting Fees and Services 24 PART IV 24 Item 15. Exhibits, Financial Statement Schedules 24 Item 16. Form 10-K Summary 24

Signatures

Signatures Exhibit Index Table of Contents This Annual Report on Form 10-K contains statements that are not statements of historical fact and are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the " Exchange Act " ), each as amended. The forward-looking statements are principally, but not exclusively, contained in " Item 1: Business " and " Item 7: Management ' s Discussion and Analysis of Financial Condition and Results of Operations. " These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about management ' s confidence or expectations, our business strategy, our ability to raise capital or borrow funds to consummate acquisitions and the availability of attractive acquisition candidates, our expectations regarding future costs of product revenues, our anticipated compliance with the covenants contained in our credit facility, the adequacy of our financial resources and our plans, objectives, expectations and intentions that are not historical facts. In some cases, you can identify forward-looking statements by terms such as " may, " " will, " " should, " " could, " " would, " " seek, " " expects, " " plans, " " aim, " " anticipates, " " believes, " " estimates, " " projects, " " predicts, " " intends, " " think, " " strategy, " " potential, " " objectives, " " optimistic, " " new, " " goal " and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on

View Full Filing

View this 10-K filing on SEC EDGAR